Is There a Biological Basis for Treatment of Fibrodysplasia Ossificans Progressiva with Rosiglitazone? Potential Benefits and Undesired Effects

Thiazolidinediones (TZDs), among which Rosiglitazone, are known agonists of the peroxisome-proliferator-activated receptor γ (PPARγ) commonly used for treatment of hyperglycemia. A recently published article describing a case report on a patient affected by Fibrodysplasia Ossificans Progressiva (FOP...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Bocciardi, Renata, Ravazzolo, Roberto
Médium: Artigo
Jazyk:Inglês
Vydáno: Hindawi Publishing Corporation 2010
Témata:
Review Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2896849/
https://ncbi.nlm.nih.gov/pubmed/20613955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2010/541927
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky